XBIT חוב כולל להון XBiotech Inc.

The market trend for the debt-to-equity ratio of XBiotech Inc. (XBIT) stands at 0.00, while the business's financial success is based on medical test outcomes, ignoring market conditions. XBiotech Inc. (XBIT) creates fully human antibodies to combat tumors, minimizing the risk of immune rejection. The technological base in Texas, featuring modular reactors, ensures bioprocess stability and high adaptability of production lines.

The financial stability of XBiotech Inc. (XBIT) during the development of innovative antibodies depends on the balance between borrowed funds and equity. This metric compares total liabilities to equity, allowing investors to assess the debt load and bankruptcy risk, which clearly reflects the current total debt-to-equity ratio while seeking strategic partners.